1 Green Flag and 1 Red Flag for Novavax’s Vaccine Candidate

Unlike the first COVID-19 vaccines to receive authorization in the U.S., Novavax’s (NASDAQ: NVAX) candidate, NVX-CoV2373, isn’t mRNA-based. Instead, it uses the tried-and-true technique of introducing proteins from a virus into the body to provoke an immune response — in this caRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario